TriangleNCT04401579 · OUTCOME
Duration of New Oxygen Use
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Days
- Interval / dispersion
- Inter-Quartile Range
- Time frame
- Day 1 through Day 29
What was measured
Duration of new oxygen use was measured in days among participants who were not on oxygen at baseline, determined two ways. The first includes imputations for participants who died. The second method is restricted to participants who did not die
Analysis population: The analysis population is restricted to randomized participants who were not on oxygen at baseline but who subsequently required oxygen.
Groups in this outcome
Remdesivir Plus Baricitinib
200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib administered orally daily for the duration of the hospitalization up to a 14-day total course.
Remdesivir Plus Placebo
200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib Placebo administered orally daily for the duration of the hospitalization up to a 14-day total course.
| Group | Source count |
|---|---|
| Remdesivir Plus Baricitinib | 16 |
| Remdesivir Plus Placebo | 29 |
Reported measurements
Including imputations for participants who died
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Remdesivir Plus Baricitinib | 3 | Not reported | 2 | 4 | Not reported |
| Remdesivir Plus Placebo | 3 | Not reported | 2 | 6 | Not reported |
Among participants who did not die
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Remdesivir Plus Baricitinib | 3 | Not reported | 2 | 4 | Not reported |
| Remdesivir Plus Placebo | 3 | Not reported | 2 | 6 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 2
- upper Limit
- 4
- value
- 3
- group Id
- OG001
- lower Limit
- 2
- upper Limit
- 6
- value
- 3
- title
- Including imputations for participants who died
- categories
- measurements
- group Id
- OG000
- lower Limit
- 2
- upper Limit
- 4
- value
- 3
- group Id
- OG001
- lower Limit
- 2
- upper Limit
- 6
- value
- 3
- title
- Among participants who did not die
- denoms
- counts
- group Id
- OG000
- value
- 16
- group Id
- OG001
- value
- 29
- units
- Participants
- description
- Duration of new oxygen use was measured in days among participants who were not on oxygen at baseline, determined two ways. The first includes imputations for participants who died. The second method is restricted to participants who did not die
- dispersion Type
- Inter-Quartile Range
- groups
- description
- 200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib administered orally daily for the duration of the hospitalization up to a 14-day total course.
- id
- OG000
- title
- Remdesivir Plus Baricitinib
- description
- 200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib Placebo administered orally daily for the duration of the hospitalization up to a 14-day total course.
- id
- OG001
- title
- Remdesivir Plus Placebo
- param Type
- MEDIAN
- population Description
- The analysis population is restricted to randomized participants who were not on oxygen at baseline but who subsequently required oxygen.
- reporting Status
- POSTED
- time Frame
- Day 1 through Day 29
- title
- Duration of New Oxygen Use
- type
- SECONDARY
- unit Of Measure
- Days
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice